Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases

合并后的公司将专注于开发针对心血管内分泌疾病的首创类下一代药物

Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study

Marea 拥有多个处于后期临床阶段的产品候选药物：用于治疗严重高甘油三酯血症（sHTG）的 MAR001/005 目前正处于 IIb 期临床试验，而用于治疗肢端肥大症的 MAR002 正在推进至 II 期临床试验。

Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028

从领先的生命科学投资者和其他机构投资者处同时获得2.25亿美元的融资，预计将支持公司运营至2028年

LIBERTY CORNER, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company, today announced that it has acquired Marea Therapeutics, Inc. (“Marea”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases..

新泽西州利伯蒂科纳，2026年9月17日（环球社讯）——临床阶段制药公司Lisata Therapeutics, Inc.（纳斯达克股票代码：LSTA）（“Lisata”）今日宣布，已收购临床阶段生物技术公司Marea Therapeutics, Inc.（“Marea”）。Marea利用人类遗传学的最新进展，致力于开发针对心血管内分泌疾病的首创型下一代药物。

Concurrent with the acquisition, Lisata entered into a definitive purchase agreement for the sale of Series C non-voting convertible preferred stock in a private placement financing, which is expected to result in gross proceeds to Lisata of approximately $225 million before deducting placement agent and other offering expenses.

与此次收购同步，Lisata 就通过私募配售融资出售 C 系列无投票权可转换优先股签订了具有约束力的购买协议，预计在扣除配售代理费及其他发行费用之前，Lisata 将获得约 2.25 亿美元的总收益。

The oversubscribed financing included participation from leading life sciences investors including RA Capital Management, Forbion, Third Rock Ventures, Alpha Wave, Perceptive Advisors, Sofinnova Investments, Omega Funds, Surveyor Capital (a Citadel company), Columbia Threadneedle Investments, Nantahala Capital, Affinity Asset Advisors, LLC, venBio, Rock Springs Capital and other institutional investors..

此次超额认购的融资吸引了多家领先的生命科学投资者参与，包括RA Capital Management、Forbion、Third Rock Ventures、Alpha Wave、Perceptive Advisors、Sofinnova Investments、Omega Funds、Surveyor Capital（Citadel旗下公司）、Columbia Threadneedle Investments、Nantahala Capital、Affinity Asset Advisors, LLC、venBio、Rock Springs Capital以及其他机构投资者。

Lisata plans to use the net proceeds primarily to advance MAR001/005 and MAR002 through key clinical milestones, including the completion of an ongoing Phase 2b trial in patients with severe hypertriglyceridemia, as well as a Phase 2 trial in patients with acromegaly. Both studies are expected to report topline data in the fourth quarter of 2027.

Lisata 计划将净收益主要用于推进 MAR001/005 和 MAR002 的关键临床里程碑，包括完成正在进行的针对严重高甘油三酯血症患者的 IIb 期临床试验，以及针对肢端肥大症患者的 II 期临床试验。预计这两项研究都将在 2027 年第四季度公布主要数据。

Remaining proceeds will be used for general corporate purposes..

剩余收益将用于一般公司用途。

“After a thorough review of strategic alternatives, the acquisition of Marea marks a significant milestone for Lisata as we broaden our focus toward advancing Marea’s product candidate portfolio, which addresses significant unmet need across a range of cardioendocrine diseases,” said Dr. David J. Mazzo, CEO of Lisata.

Lisata 首席执行官 David J. Mazzo 博士表示：“在对战略替代方案进行全面评估后，收购 Marea 标志着 Lisata 的一个重要里程碑。我们将进一步聚焦于推进 Marea 的产品候选管线，以满足一系列心血管内分泌疾病领域尚未被满足的重大医疗需求。”

“This pipeline, led by MAR001, is designed to overcome the limitations of current treatment paradigms and has the potential to establish a new standard of care in the treatment of severe hypertriglyceridemia (sHTG). With a strong balance sheet, we believe that we are well-positioned to drive these programs through their next stages of development and ultimately deliver meaningful benefit to patients.

“由MAR001主导的该研发管线旨在克服当前治疗模式的局限性，并有望为严重高甘油三酯血症（sHTG）的治疗确立新的标准护理方案。凭借稳健的财务状况，我们相信我们有能力推动这些项目进入下一阶段的开发，并最终为患者带来显著的临床获益。”

We believe that this acquisition, in combination with our parallel efforts to evaluate possible next steps in the development of certepetide, can provide long-term value to our shareholders.”.

我们相信，此次收购与我们为评估certepetide开发下一步可能举措而并行开展的工作相结合，能够为我们的股东创造长期价值。

“This transaction provides the combined company with the resources to advance our two clinical stage drug candidates through pivotal milestones, including MAR001 topline Phase 2b data in severe hypertriglyceridemia and MAR002 Phase 2 proof of concept data in patients with acromegaly next year, as well as initiation of Phase 3 registrational studies for both programs,” said Dr.

“此次交易为合并后的公司提供了资源，以推动我们两款处于临床阶段的候选药物取得关键里程碑进展，包括明年公布MAR001在治疗重度高甘油三酯血症方面的2b期试验顶线数据，以及MAR002在肢端肥大症患者中的2期概念验证数据，并启动这两个项目的3期注册研究。”博士表示。

Josh Lehrer, newly appointed Chief Operating Officer and President of Lisata Therapeutics and Chief Executive Officer of Marea. “Joining with Lisata gives our first-in-class antibody programs a faster path to patients who today have limited options for these serious cardioendocrine diseases, and we're grateful for the continued confidence of our new and existing investors.”.

乔什·莱勒（Josh Lehrer）新任Lisata Therapeutics首席运营官兼总裁，以及Marea首席执行官。“与Lisata合作为我们首创的抗体项目提供了更快的途径，使患有这些严重心血管内分泌疾病且目前治疗选择有限的患者能够早日受益。我们感谢新老投资者持续的信任。”

About the Transactions

关于交易

The acquisition of Marea was structured as a stock-for-stock transaction pursuant to which all of Marea’s outstanding equity interests were exchanged based on a fixed exchange ratio for a combination of 1,793,129 shares of Lisata common stock and 211,365.213 shares of Series C non-voting convertible preferred stock (representing in the aggregate 213,158,342 shares of Lisata common stock on an as-converted-to-common stock basis), in each case, calculated on a fully-diluted basis (and without giving effect to any beneficial ownership limitations).

Marea的收购被构建为一项以股换股交易，根据该交易，Marea的所有未偿股权益按照固定交换比率，置换为1,793,129股Lisata普通股和211,365.213股C系列无投票权可转换优先股的组合（按转换为普通股的基础计算，合计相当于213,158,342股Lisata普通股），在每种情况下，均按完全稀释基础计算（且不考虑任何实益所有权限制）。

Concurrently with the acquisition of Marea, Lisata entered into a definitive purchase agreement for a private placement financing with leading life sciences investors and other institutional investors to raise $225 million in which the investors will be issued an aggregate of 150,867.995 shares of Series C non-voting convertible preferred stock (or 150,867,995 shares of Lisata common stock on an as-converted-to-common stock basis and without giving effect to any beneficial ownership limitations) at a price of approximately $1,491.37 per share (or approximately $1.4914 per share of common stock on an as-converted-to-common stock basis).

在与收购Marea同时，Lisata与领先的生命科学投资者及其他机构投资者签订了定向增发融资的最终购买协议，以筹集2.25亿美元。根据该协议，投资者将获得总计150,867.995股C系列无投票权可转换优先股（或在转换为普通股的基础上，且不考虑任何实益所有权限制的情况下，相当于150,867,995股Lisata普通股），每股价格约为1,491.37美元（或在转换为普通股的基础上，每股普通股价格约为1.4914美元）。

Subject to Lisata stockholder approval, each share of Series C non-voting convertible preferred stock will automatically convert into 1,000 shares of common stock, subject to certain beneficial ownership limitations set by each holder. As a result of the transactions, equity holders of Lisata immediately prior to the acquisition will own approximately 2.39% of Lisata’s common stock, equity holders of Marea immediately prior to the acquisition will own approximately 59.54% of Lisata’s common stock and investors in the private placement financing will own approximately 38.07% of Lisata’s common stoc.

在获得Lisata股东批准的前提下，每股C系列无投票权可转换优先股将自动转换为1,000股普通股，但须遵守各持有人设定的某些实益所有权限制。交易完成后，收购前即刻的Lisata权益持有人将拥有Lisata约2.39%的普通股，收购前即刻的Marea权益持有人将拥有Lisata约59.54%的普通股，而私募配售融资的投资者将拥有Lisata约38.07%的普通股。

The acquisition was approved by the Board of Directors of Lisata and the Board of Directors and stockholders of Marea. The acquisition and private placement financing were not subject to the approval of Lisata’s stockholders. The approval of Lisata’s stockholders is required under the terms of the Series C non-voting convertible preferred stock in order for the Series C non-voting convertible preferred stock to be converted into shares of Lisata common stock, and Lisata is required to hold a stockholder meeting for such vote.

该收购已获得Lisata董事会以及Marea董事会和股东的批准。该收购及私募配售融资无需获得Lisata股东的批准。根据C系列无投票权可转换优先股的条款，须获得Lisata股东的批准，方可将C系列无投票权可转换优先股转换为Lisata普通股股份，且Lisata须为此召开股东会议进行表决。

On an as-converted basis and after accounting for these transactions (and without giving effect to any beneficial ownership limitations), the total number of shares of Lisata common stock (including shares underlying the Series C non-voting convertible preferred stock) will be approximately 396,315,542..

在按转换后基础并考虑上述交易（且不考虑任何受益所有权限制）的情况下，Lisata 普通股（包括 C 系列无投票权可转换优先股所对应的股份）的股份总数将约为 396,315,542 股。

H.C. Wainwright is serving as financial advisor to Lisata. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. is serving as legal counsel to Lisata. Leerink Partners is serving as financial advisor to Marea. Jefferies, Leerink Partners, Guggenheim Securities, Cantor and LifeSci Capital are acting as placement agents for the concurrent private placement financing. Goodwin Procter LLP is serving as legal counsel to Marea.

H.C. Wainwright 担任 Lisata 的财务顾问。Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 担任 Lisata 的法律顾问。Leerink Partners 担任 Marea 的财务顾问。Jefferies、Leerink Partners、Guggenheim Securities、Cantor 和 LifeSci Capital 担任本次同步私募配售融资的配售代理。Goodwin Procter LLP 担任 Marea 的法律顾问。

Cooley LLP is serving as legal counsel to the placement agents..

库利律师事务所正担任配售代理的法律顾问。

About Lisata Therapeutics

关于 Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively.

Lisata Therapeutics 是一家处于临床阶段的制药公司，致力于发现、开发和商业化用于治疗晚期实体瘤及其他重大疾病的创新疗法。Lisata 的环肽候选产品 certepetide 是一种研究性药物，旨在激活一种新型摄取通路，使联合给药或偶联的抗癌药物能够更有效地选择性靶向并渗透实体瘤。

Lisata has established noteworthy partnerships based on its CendR Platform.

Lisata 基于其 CendR 平台建立了引人注目的合作伙伴关系。

®

®

technology. For a comprehensive overview of certepetide's mechanism of action, please view our informative short film.

技术。如需全面了解 certepetide 的作用机制，请观看我们的科普短片。

About Marea Therapeutics

关于 Marea Therapeutics

Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead product candidate, MAR001, is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels.

Marea Therapeutics 是一家临床阶段的生物技术公司，利用人类遗传学的最新进展，开发针对心血管内分泌疾病的首创型下一代药物。公司的主要候选产品 MAR001 正处于治疗重度高甘油三酯血症（sHTG）的 IIb 期临床开发阶段，该病症以极高的甘油三酯水平为特征。

The company is also advancing MAR002 for the treatment of acromegaly..

该公司也在推进MAR002用于治疗肢端肥大症。

About MAR001/005

关于 MAR001/005

MAR001 is a potential first-in-class monoclonal antibody in clinical development that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower triglycerides and improve adipose tissue function.

MAR001 是一款处于临床开发阶段的潜在首创单克隆抗体，靶向在脂肪组织中高度表达的 ANGPTL4 蛋白。通过抑制 ANGPTL4 从而增强脂蛋白脂肪酶（LPL）活性，MAR001 旨在降低甘油三酯水平并改善脂肪组织功能。

Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower triglyceride levels, improved adipose distribution, better insulin sensitivity, and protection from cardiovascular disease and type 2 diabetes..

人类遗传学数据已确定ANGPTL4是一个极具前景的治疗靶点，因为其功能丧失等位基因可导致甘油三酯水平降低、脂肪分布改善、胰岛素敏感性提高，并对心血管疾病和2型糖尿病具有保护作用。

MAR005, a half-life-extended version of MAR001 with an improved pharmacokinetic profile, is Marea's planned Phase 3 candidate and is in clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity.

MAR005是MAR001的半衰期延长版本，具有更优的药代动力学特征，是Marea公司计划推进至III期临床试验的候选药物，目前正处于临床开发阶段，用于治疗以甘油三酯水平极高为特征的重度高甘油三酯血症（sHTG）。MAR001的临床前模型研究显示，其可降低甘油三酯、残余胆固醇和异位脂肪，并改善胰岛素敏感性。

MAR001 has demonstrated strong Phase 1a and 2a results and is in Phase 2b clinical development..

MAR001 已展现出强劲的 1a 期和 2a 期临床试验结果，目前正处于 2b 期临床开发阶段。

About Severe Hypertriglyceridemia (sHTG)

关于重度高甘油三酯血症（sHTG）

Severe hypertriglyceridemia (sHTG) is a serious and often under-recognized metabolic condition marked by triglyceride levels high enough to place patients at significant risk of acute pancreatitis, a painful and potentially life-threatening complication that frequently results in hospitalization. Patients with sHTG also commonly present with a broader burden of cardiometabolic comorbidities, including insulin resistance, type 2 diabetes, and cardiovascular disease, compounding the overall health risks associated with the condition.

重度高甘油三酯血症（sHTG）是一种严重且常被忽视的代谢性疾病，其特征为甘油三酯水平升高至使患者面临急性胰腺炎的显著风险。急性胰腺炎是一种疼痛性且可能危及生命的并发症，常导致住院。sHTG患者还通常伴有更广泛的心血管代谢共病负担，包括胰岛素抵抗、2型糖尿病和心血管疾病，从而加剧了与该疾病相关的整体健康风险。

Despite the availability of lifestyle modification and existing lipid-lowering therapies, many patients with sHTG continue to experience dangerously elevated triglycerides and recurrent pancreatitis events, underscoring a persistent gap in disease management..

尽管已有生活方式干预和现有的降脂疗法，许多严重高甘油三酯血症（sHTG）患者仍持续面临危险性的甘油三酯升高和复发性胰腺炎事件，这凸显了疾病管理中依然存在的显著差距。

About MAR002

关于 MAR002

MAR002 is a potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. The

MAR002 是一种强效、选择性、半衰期延长的变构人源单克隆生长激素受体拮抗剂（GHRA）抗体，正在开发用于治疗肢端肥大症。

in vivo

体内

PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly.

MAR002的药代动力学（PK）和药效动力学（PD）特性可预测，且符合半衰期延长的人源抗体的典型特征，显示出与作用持续时间较长相一致的特性，适用于人类皮下注射给药的频率较低。这些特性支持其为肢端肥大症患者提供有效且便捷治疗的潜力。

In a Phase 1 study in healthy volunteers, MAR002 achieved proof-of-concept dose-dependent suppression of IGF-1, and was generally well tolerated with no serious adverse events. Marea is currently evaluating MAR002 in a Phase 2 trial of patients with acromegaly..

在一项针对健康志愿者的1期研究中，MAR002实现了概念验证，显示出对IGF-1的剂量依赖性抑制作用，且总体耐受性良好，未发生严重不良事件。Marea目前正在一项针对肢端肥大症患者的2期临床试验中对MAR002进行评估。

About Acromegaly

关于肢端肥大症

Acromegaly is an orphan disease characterized by the excess secretion of growth hormone (GH) from a benign pituitary adenoma. Acromegaly affects approximately 30,000 patients in the U.S. If left untreated, acromegaly is highly morbid, leading to significant comorbidities such as GH-induced insulin resistance and diabetes, and serious cardiovascular pathology.

肢端肥大症是一种罕见病，其特征为良性垂体腺瘤过度分泌生长激素（GH）。在美国，肢端肥大症影响约30,000名患者。若不予治疗，肢端肥大症会导致极高的发病率，引发严重的合并症，如GH诱导的胰岛素抵抗和糖尿病，以及严重的心血管病理改变。

The median lifespan of patients can be shortened by 10 years without effective therapy, and incomplete IGF-1 normalization is associated with increased mortality. Despite its severity, acromegaly is often under or misdiagnosed, with an average time from symptom onset to diagnosis of approximately eight years..

若无有效治疗，患者的中位生存期可能缩短10年，且胰岛素样生长因子-1（IGF-1）未能完全正常化与死亡率升高相关。尽管肢端肥大症病情严重，但该病常被漏诊或误诊，从症状出现到确诊的平均时间约为八年。

The current treatment paradigm for acromegaly often involves surgery, performed in over 90% of patients, which achieves remission in about 50% of cases, though this can degrade over time. Medical therapy is required for approximately 65% (around 20,000 in the U.S.) of patients during their disease journey.

肢端肥大症的现行治疗范式通常包括手术，超过90%的患者接受手术治疗，约50%的病例可实现缓解，但缓解效果可能随时间推移而减退。在疾病病程中，约65%的患者（美国约为20,000人）需要药物治疗。

Current medical treatments include somatostatin receptor ligands (SRLs) and GHRA pegvisomant. However, most patients do not achieve biochemical control with existing therapies..

当前的医学治疗包括生长抑素受体配体（SRLs）和GHRA培维索孟。然而，大多数患者通过现有疗法无法实现生化控制。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Lisata, Marea, the concurrent private placement financing and the acquisition of Marea by Lisata (the “Transactions”) and other matters.

本新闻稿中除纯粹历史事实信息外的某些陈述，可能构成联邦证券法律意义上的“前瞻性陈述”，包括为适用美国《1995年私人证券诉讼改革法》下的安全港条款而作出的、涉及Lisata、Marea、同步进行的私募配售融资以及Lisata收购Marea（统称“交易”）及其他事项的陈述。

These forward-looking statements include, but are not limited to, express or implied statements relating to the company’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Transactions, including the closing of the concurrent private placement financing, and the expected effects, perceived benefits or opportunities and related timing with respect thereto; expectations regarding or plans for Marea’s pipeline, including its ongoing clinical trials, research and development programs and the expected timing for key milestones, including the release of clinical data; the potential benefits of MAR001/005 and MAR002; and expectations regarding the use of proceeds from the concurrent private placement financing and cash runway expectations therefrom, including such proceeds funding the company through key clinical milestones.

这些前瞻性陈述包括但不限于，与公司未来相关的预期、希望、信念、意图或战略的明示或暗示陈述，包括（但不限于）以下方面的陈述：交易事项，包括同步私募融资的交割，以及与之相关的预期影响、认知收益或机会和相关时间安排；对Marea产品管线的预期或计划，包括其正在进行的临床试验、研发项目以及关键里程碑（包括临床数据发布）的预期时间安排；MAR001/005和MAR002的潜在益处；以及对同步私募融资所得款项用途的预期及由此产生的现金跑道预期，包括该等所得款项为公司提供资金以支持其实现关键临床里程碑。

In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “aim,” “strategy,” “target,” “seek,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,”.

此外，任何提及预测、预估或对未来事件或情况的其他描述（包括任何基本假设）的陈述均为前瞻性陈述。这些词语包括“机会”、“潜力”、“里程碑”、“管线”、“能够”、“目标”、“旨在”、“战略”、“靶点”、“寻求”、“预期”、“实现”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“打算”、“可以”、“或许”。

Contacts:

联系人：

Lisata:

利萨塔：

Investors and Media:

投资者与媒体：

John Menditto

约翰·门迪托

jmenditto@lisata.com

jmenditto@lisata.com

Marea:

马雷亚：

Media:

媒体：

1AB

1AB

Katie Engleman

凯蒂·恩格尔曼

katie@1abmedia.com

katie@1abmedia.com

Investors:

投资者：

Meru Advisors

梅鲁顾问公司

Lauren Glaser

劳伦·格拉瑟

lglaser@meruadvisors.com

lglaser@meruadvisors.com